GenoTech Solutions develops genotype-guided antifibrotic therapies targeting the genetic drivers of liver fibrosis in MASH patients.
Explore Our Pipeline ↓GenoTech Solutions SAS is a preclinical-stage French biotechnology company developing a new class of genotype-guided antifibrotic therapies for metabolic dysfunction-associated steatohepatitis (MASH) with advanced hepatic fibrosis.
Our approach is built on twenty years of human genetic research demonstrating that germline variants in specific fibrogenic pathways act as master regulators of fibrosis severity across aetiologies and populations. These discoveries enable a precision medicine strategy where patients are stratified by genotype and treated with therapies matched to their molecular drivers.
Current approved MASH therapies achieve only 26–36% fibrosis improvement, leaving 64–74% of patients as non-responders. GenoTech addresses this unmet need with direct antifibrotic mechanisms and companion diagnostics to identify the patients most likely to benefit.
Repositioning of an approved drug with 15+ years of clinical safety data for a new antifibrotic indication in MASH. Genotype-guided patient selection via proprietary companion diagnostic.
Discovery of a first-in-class small molecule inhibitor targeting a key protein–protein interaction in the fibrogenic transcriptional cascade. Inherent isoform selectivity validated computationally.
Dual-pathway blockade interrupting the self-reinforcing fibrotic loop at both the transcriptional and hemodynamic nodes simultaneously. Expected superiority over monotherapy.
Proprietary SNP-based companion diagnostic identifying patients with genetically-driven rapid fibrosis progression. Enables precision enrichment of clinical trials and targeted prescribing.
Germline variants in fibrogenic pathways identified as master regulators of fibrosis severity in cohorts spanning Chinese, Sudanese, Brazilian, Ugandan, and European populations. Odds ratios 1.5–4.0 across aetiologies.
Partnership with leading computational chemistry platforms for structure-based drug discovery. Homology modelling, pharmacophore generation, and virtual screening of >8 million compounds to identify selective hit molecules.
Companion diagnostic development enabling genotype-guided clinical trial enrichment. Standard of Care Plus design layered on existing metabolic therapies to address the residual fibrosis gap (64–74% non-responders).
Co-founder. Background in pharmaceutical R&D, drug discovery programme management, translational medicine, and biotech operations. Leads scientific strategy, IP development, CRO partnerships, and investor relations. Responsible for the design and execution of both GT-001 and GT-002 programmes.
25+ years of research in the genetics of hepatic fibrosis. Pioneered the identification of genetic determinants of fibrosis severity across multiple populations and aetiologies. Over 200 peer-reviewed publications. INSERM research director. Founder of the genetic epidemiology programme that underlies GenoTech’s therapeutic platform.
GenoTech Solutions is actively seeking strategic partnerships and Series A investment to advance its antifibrotic pipeline through clinical proof-of-concept.
laurent.gros@genotech.tech